Can Fite Biofarma Ltd (CANF)
2.10
-0.01
(-0.47%)
USD |
NYAM |
May 07, 14:17
Can Fite Biofarma Cash and Short Term Investments (Quarterly): 8.922M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 8.922M |
September 30, 2023 | 7.942M |
June 30, 2023 | 9.616M |
March 31, 2023 | 12.42M |
December 31, 2022 | 7.987M |
September 30, 2022 | 10.81M |
June 30, 2022 | 12.77M |
March 31, 2022 | 16.70M |
December 31, 2021 | 19.14M |
September 30, 2021 | 13.66M |
June 30, 2021 | 7.808M |
March 31, 2021 | 11.61M |
December 31, 2020 | 8.343M |
September 30, 2020 | 10.28M |
June 30, 2020 | 9.137M |
December 31, 2019 | 2.761M |
September 30, 2019 | 4.793M |
June 30, 2019 | 8.38M |
March 31, 2019 | 3.206M |
December 31, 2018 | 3.888M |
September 30, 2018 | 5.728M |
June 30, 2018 | 5.84M |
March 31, 2018 | 8.314M |
December 31, 2017 | 3.505M |
September 30, 2017 | 5.105M |
Date | Value |
---|---|
June 30, 2017 | 6.876M |
March 31, 2017 | 9.777M |
December 31, 2016 | 8.112M |
September 30, 2016 | 10.01M |
June 30, 2016 | 12.04M |
March 31, 2016 | 14.97M |
December 31, 2015 | 16.91M |
September 30, 2015 | 14.44M |
June 30, 2015 | 7.725M |
March 31, 2015 | 9.018M |
December 31, 2014 | 9.268M |
September 30, 2014 | 4.128M |
June 30, 2014 | 5.589M |
March 31, 2014 | 7.830M |
December 31, 2013 | 5.963M |
September 30, 2013 | 2.711M |
June 30, 2013 | 4.094M |
March 31, 2013 | 5.250M |
December 31, 2012 | 1.145M |
September 30, 2012 | 1.910M |
June 30, 2012 | 2.659M |
March 31, 2012 | 2.754M |
December 31, 2011 | 3.842M |
September 30, 2011 | 0.4772M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
2.761M
Minimum
Dec 2019
19.14M
Maximum
Dec 2021
10.17M
Average
9.376M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
Compugen Ltd | 50.68M |
Pluri Inc | 30.62M |
BioLine Rx Ltd | 42.99M |
XTL Biopharmaceuticals Ltd | 2.006M |
BiomX Inc | 14.91M |